Human medicines European public assessment report (EPAR): Enwylma, denosumab, Date of authorisation: 26/06/2025, Revision: 1, Status: Authorised

Enwylma RSS Authorised This medicine is authorised for use in the European Union denosumab Medicine Human Authorised Application under evaluation CHMP opinion European Commission decision Overview Enwylma is a medicine used to prevent bone complications in adults with advanced cancer that has spread to the bone. These complications include fractures (breaks in the bone), spinal compression (pressure on the spinal cord caused by damage to the surrounding bone), or bone problems requiring radiotherapy (treatment with radiation) or surgery. Enwylma is also used to treat a type of bone cancer called giant cell tumour of bone in adults and adolescents whose bones have fully developed. It is used in patients who cannot be treated by surgery or in whom surgery is likely to cause complications. Enwylma contains the active substance denosumab and is a biological medicine. It is a ‘biosimilar medicine’; this means that Enwylma is highly similar to another biological medicine (the ‘reference medicine’) that is already authorised in the EU. The reference medicine for Enwylma is Xgeva. For more information on biosimilar medicines, see here . Expand section Collapse section How is Enwylma used? Enwylma can only be obtained with a prescription. It is available as a solution for injection under the skin in the thigh, belly or upper arm. To prevent bone complications in cancer that has spread to the bone, the medicine is given once every 4 weeks as a single injection under the skin. In patients with giant cell tumour of bone, it is injected under the skin once a week for 3 weeks, and then once every 4 weeks. Patients should take calcium and vitamin D supplements while being treated with Enwylma. For more information about using Enwylma, see the package leaflet or contact your doctor or pharmacist. How does Enwylma work? The active substance in Enwylma, denosumab, is a monoclonal antibody which has been designed to recognise and attach to a protein called RANKL. This protein activates osteoclasts, the cells in the body that are involved in breaking down bone tissue. By attaching to RANKL and blocking it, denosumab reduces the formation and activity of the osteoclasts. This reduces the loss of bone, making fractures and other serious bone complications less likely. RANKL is also involved in activating the osteoclast-like cells in giant cell tumour of bone. Treatment with denosumab therefore prevents them from growing and breaking down bone, allowing normal bone to replace the tumour. What benefits of Enwylma have been shown in studies? Laboratory studies comparing Enwylma with Xgeva have shown that the active substance in Enwylma is highly similar to that in Xgeva in terms of structure, purity and biological activity. Studies have also shown that giving Enwylma produces similar levels of the active substance in the body to those seen with Xgeva. In addition, a study compared the effectiveness of the denosumab in Enwylma with that of another medicine containing denosumab in 558 women with osteoporosis (a disease that makes bones fragile) who have been through the menopause. After a year of treatment, bone mineral density in the spine (a measure of how strong the bones are) increased by around 5.5 % in both women who received Enwylma and those who received the other denosumab medicine. Because denosumab works in a similar way in osteoporosis and in the conditions Enwylma is intended to treat, a specific study on the effectiveness of Enwylma in these conditions is not needed. What are the risks associated with Enwylma? The safety of Enwylma has been evaluated and, based on all the studies carried out, the side effects of the medicine are considered to be comparable to those of the reference medicine Xgeva. For the complete list of side effects and restrictions of Enwylma, see the package leaflet. The most common side effects with Enwylma (which may affect more than 1 in 10 people) include hypocalcaemia (low levels of calcium in the blood) and musculoskeletal pain (pain in the muscles and bones). Other common side effects (which may affect up to 1 in 10 people) include osteonecrosis in the jaw (damage to the bones of the jaw, which could lead to pain, sores in the mouth and loose teeth). Hypocalcaemia mostly occurs within the first 2 weeks of starting treatment and can be severe; however, it can be managed with calcium and vitamin D supplementation. Enwylma must not be used in patients with wounds from dental or mouth surgery that have not yet healed, or in people with severe, untreated hypocalcaemia. Why is Enwylma authorised in the EU? The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Enwylma has a highly similar structure, purity and biological activity to Xgeva and is distributed in the body in the same way. In addition, a study has shown that Enwylma is as effective as another denosumab-containing medicine in women with osteoporosis. Denosumab works in a similar way in the treatment of osteoporosis and in Enwylma’s intended uses. All these data were considered sufficient to conclude that Enwylma will have the same effects as Xgeva in its authorised uses. Therefore, the Agency’s view was that, as for Xgeva, the benefits of Enwylma outweigh the identified risks and it can be authorised for use in the EU. What measures are being taken to ensure the safe and effective use of Enwylma? The company that markets Enwylma will provide a card to inform patients about the risk of osteonecrosis of the jaw and to instruct them to contact their doctor if they have symptoms. Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Enwylma have also been included in the summary of product characteristics and the package leaflet. As for all medicines, data on the use of Enwylma are continuously monitored. Suspected side effects reported with Enwylma are carefully evaluated and any necessary action taken to protect patients. Other information about Enwylma Enwylma received a marketing authorisation valid throughout the EU on 26 June 2025. Enwylma : EPAR - Medicine overview Reference Number: EMA/162601/2025 English (EN) (123.82 KB - PDF) First published: 18/11/2025 View Other languages (22) български (BG) (147.06 KB - PDF) First published: 18/11/2025 View español (ES) (122.66 KB - PDF) First published: 18/11/2025 View čeština (CS) (146.46 KB - PDF) First published: 18/11/2025 View dansk (DA) (122.74 KB - PDF) First published: 18/11/2025 View Deutsch (DE) (126 KB - PDF) First published: 18/11/2025 View eesti keel (ET) (119.57 KB - PDF) First published: 18/11/2025 View ελληνικά (EL) (146.44 KB - PDF) First published: 18/11/2025 View français (FR) (123.84 KB - PDF) First published: 18/11/2025 View hrvatski (HR) (145.05 KB - PDF) First published: 18/11/2025 View italiano (IT) (121.63 KB - PDF) First published: 18/11/2025 View latviešu valoda (LV) (151.98 KB - PDF) First published: 18/11/2025 View lietuvių kalba (LT) (143.38 KB - PDF) First published: 18/11/2025 View magyar (HU) (143.91 KB - PDF) First published: 18/11/2025 View Malti (MT) (146.9 KB - PDF) First published: 18/11/2025 View Nederlands (NL) (123.53 KB - PDF) First published: 18/11/2025 View polski (PL) (149.45 KB - PDF) First published: 18/11/2025 View português (PT) (123.23 KB - PDF) First published: 18/11/2025 View română (RO) (141.2 KB - PDF) First published: 18/11/2025 View slovenčina (SK) (145.11 KB - PDF) First published: 18/11/2025 View slovenščina (SL) (142.79 KB - PDF) First published: 18/11/2025 View Suomi (FI) (118.8 KB - PDF) First published: 18/11/2025 View svenska (SV) (120.32 KB - PDF) First published: 18/11/2025 View Enwylma : EPAR - Risk management plan English (EN) (4.95 MB - PDF) First published: 18/11/2025 View Product information Enwylma : EPAR - Product information English (EN) (337.28 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View Other languages (24) български (BG) (445.17 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View español (ES) (336.99 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View čeština (CS) (383.84 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View dansk (DA) (359.81 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View Deutsch (DE) (380.83 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View eesti keel (ET) (351.07 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View ελληνικά (EL) (472.81 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View français (FR) (390.53 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View hrvatski (HR) (465.09 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View íslenska (IS) (352.52 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View italiano (IT) (370.68 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View latviešu valoda (LV) (428.43 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View lietuvių kalba (LT) (594.17 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View magyar (HU) (463.71 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View Malti (MT) (431.58 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View Nederlands (NL) (352.02 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View norsk (NO) (368.47 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View polski (PL) (417.6 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View português (PT) (351.29 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View română (RO) (658.14 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View slovenčina (SK) (581.74 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View slovenščina (SL) (416.77 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View Suomi (FI) (348 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View svenska (SV) (373.41 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View Latest procedure affecting product information: VR/0000337514 15/04/2026 This medicine’s product information is available in all official EU languages . Select 'available languages' to access the language you need. Product information documents contain: summary of product characteristics (annex I); manufacturing authorisation holder responsible for batch release (annex IIA); conditions of the marketing authorisation (annex IIB); labelling (annex IIIA); package leaflet (annex IIIB). Enwylma : EPAR - All authorised presentations English (EN) (19.5 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View Other languages (24) български (BG) (42.66 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View español (ES) (19.51 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View čeština (CS) (40.62 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View dansk (DA) (19.53 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View Deutsch (DE) (28.94 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View eesti keel (ET) (19.75 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View ελληνικά (EL) (40.76 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View français (FR) (29.46 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View hrvatski (HR) (36.05 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View íslenska (IS) (19.46 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View italiano (IT) (58.32 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View latviešu valoda (LV) (56.19 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View lietuvių kalba (LT) (49.55 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View magyar (HU) (36.84 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View Malti (MT) (41.83 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View Nederlands (NL) (22.08 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View norsk (NO) (19.19 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View polski (PL) (44.96 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View português (PT) (22.49 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View română (RO) (63.11 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View slovenčina (SK) (38.9 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View slovenščina (SL) (26.97 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View Suomi (FI) (29.5 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View svenska (SV) (18.68 KB - PDF) First published: 18/11/2025 Last updated: 16/04/2026 View Product details Name of medicine Enwylma International non-proprietary name (INN) or common name denosumab Therapeutic area (MeSH) Neoplasms, Bone Tissue Giant Cell Tumor of Bone Anatomical therapeutic chemical (ATC) code M05BX04 Pharmacotherapeutic group Drugs for treatment of bone diseases Therapeutic indication Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone (see section 5.1). Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity. Authorisation details EMA product number EMEA/H/C/006376 Additional monitoring This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring . Biosimilar This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the ‘reference medicine’. For more information, see Biosimilar medicines . Marketing authorisation holder Zentiva k.s. U Kabelovny 130 102 37 Prague 10 Czech Republic Opinion adopted 25/04/2025 Marketing authorisation issued 26/06/2025 Revision 1 Assessment history Expand section Collapse section Changes since initial authorisation of medicine Enwylma : EPAR - Procedural steps taken and scientific information after authorisation English (EN) (123.87 KB - PDF) First published: 16/04/2026 View Initial marketing authorisation documents Enwylma : EPAR - Public assessment report Adopted Reference Number: EMA/165176/2025 English (EN) (8.02 MB - PDF) First published: 18/11/2025 View CHMP summary of positive opinion for Enwylma Adopted Reference Number: EMA/CHMP/132987/2025 English (EN) (155.41 KB - PDF) First published: 25/04/2025 View News on Enwylma Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2025 25/04/2025 This page was last updated on 16/04/2026 Share this page